Press Releases
  Date Title View
Nov 7, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: ...
PDF
Nov 3, 2017
Collaboration with Jazz Pharmaceuticals Accelerates Development of Early-Stage ADC Assets and Strengthens Financial Position $100+ Million Follow-on Financing Provides Two-year Operating Runway Presentations Accepted for ASH Annual Meeting Highlight Potential of Novel IGN Portfolio...
PDF
Nov 1, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three abstracts highlighting two of the Company's experimental ADC therapies, IMGN632 and IMGN779, have been acce...
PDF
Oct 20, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 fina...
PDF
Oct 16, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) applicat...
PDF
Oct 11, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock, including 2,175,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional ...
PDF
Oct 5, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price of $6.50 per share, before underwriting discounts. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up ...
PDF
Oct 4, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced that it intends to offer and sell, subject to market and other conditions, 13,000,000 shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to a...
PDF
Sep 5, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: ...
PDF
Sep 1, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021. Pursuant to the exchange agreements, the Company ...
PDF
Aug 29, 2017
Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75 million upfront payment, up to $100 million in research support, a co-commercialization option, and potential future opt-in fees, milestones and royaltie...
PDF
Aug 1, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David Johnston, chief financial officer, will present at the upcoming Canaccord Genuity Growth Conference. The pr...
PDF
Jul 28, 2017
Data Presented at ASCO Support Broad Potential of Mirvetuximab Soravtansine in Ovarian Cancer Sanofi and Debiopharm Transactions Strengthen Cash Position Conference Call to be Held at 8:00am ET Today WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, ...
PDF
Jul 14, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 28, 2017, to discuss its second quarter 2017 finan...
PDF
Jun 26, 2017
Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities Dose-dependent biological and anti-leukemia activity observed WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field...
PDF
May 30, 2017
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugate...
PDF
May 24, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, president and chief executive officer, will present at the upcoming Jefferies 2017 Global Healthcare Conferen...
PDF
May 23, 2017
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.-...
PDF
May 17, 2017
Pooled analyses of Phase 1 expansion cohorts demonstrate clinically meaningful activity in patient population being studied in FORWARD I registration trial Top-line data from FORWARD II indicate favorable safety and efficacy profile in multiple combinations Conference call...
PDF
May 5, 2017
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Activated in North America and Europe Data at AACR and SGO Annual Meetings Highlight Patient Selection Strategy for FORWARD I and Breadth of ADC Expertise Mirvetuximab Soravtansine Safety and Efficacy Data to be Presented at ...
PDF
1
... NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue